278 results on '"Sadowski, Samira M."'
Search Results
2. Surgical Management and Long-Term Evaluation of Pancreatic Neuroendocrine Tumors
3. Thyroid and Parathyroid Cancer Surgery
4. Contralateral Suppression Index Does Not Predict Clinical Cure in Patients Undergoing Surgery for Primary Aldosteronism
5. NIFT-P: Are they indolent tumors? Results of a multi-institutional study
6. Figure 5 from Upregulation of Somatostatin Receptor Type 2 Improves 177Lu-DOTATATE Therapy in Receptor-Deficient Pancreatic Neuroendocrine Tumor Model
7. Figure 2 from Upregulation of Somatostatin Receptor Type 2 Improves 177Lu-DOTATATE Therapy in Receptor-Deficient Pancreatic Neuroendocrine Tumor Model
8. Figure 4 from Upregulation of Somatostatin Receptor Type 2 Improves 177Lu-DOTATATE Therapy in Receptor-Deficient Pancreatic Neuroendocrine Tumor Model
9. Figure 3 from Upregulation of Somatostatin Receptor Type 2 Improves 177Lu-DOTATATE Therapy in Receptor-Deficient Pancreatic Neuroendocrine Tumor Model
10. Figure S1, Figure S2, Figure S3, Figure S4, Figure S5, Figure S6, Table S1 from Upregulation of Somatostatin Receptor Type 2 Improves 177Lu-DOTATATE Therapy in Receptor-Deficient Pancreatic Neuroendocrine Tumor Model
11. Figure 1 from Upregulation of Somatostatin Receptor Type 2 Improves 177Lu-DOTATATE Therapy in Receptor-Deficient Pancreatic Neuroendocrine Tumor Model
12. Data from Upregulation of Somatostatin Receptor Type 2 Improves 177Lu-DOTATATE Therapy in Receptor-Deficient Pancreatic Neuroendocrine Tumor Model
13. Prognostic Utility of Total 68Ga-DOTATATE-Avid Tumor Volume in Patients With Neuroendocrine Tumors
14. Models in Pancreatic Neuroendocrine Neoplasms: Current Perspectives and Future Directions
15. Pediatric patients with pheochromocytoma and paraganglioma should have routine preoperative genetic testing for common susceptibility genes in addition to imaging to detect extra-adrenal and metastatic tumors
16. SDHB mutation status and tumor size but not tumor grade are important predictors of clinical outcome in pheochromocytoma and abdominal paraganglioma
17. The first pancreatic neuroendocrine tumor in Li-Fraumeni syndrome: a case report
18. Incidence and management of postoperative hyperglycemia in patients undergoing insulinoma resection
19. Improvement of Lung NET Management through Standardized Care—A Swiss Nationwide Observational Study
20. Supplemental Figure 1 from miR30a Inhibits LOX Expression and Anaplastic Thyroid Cancer Progression
21. Supplemental data from miR30a Inhibits LOX Expression and Anaplastic Thyroid Cancer Progression
22. Supplemental Figure 3 from miR30a Inhibits LOX Expression and Anaplastic Thyroid Cancer Progression
23. Data from miR30a Inhibits LOX Expression and Anaplastic Thyroid Cancer Progression
24. Supplemental Figure 2 from miR30a Inhibits LOX Expression and Anaplastic Thyroid Cancer Progression
25. Germline and somatic inactivating FLCN variants in parathyroid cancer and atypical parathyroid tumors
26. Multiple Layers of Epigenetic Regulation Cooperate to Silence Expression of Somatostatin Receptor Type 2 in Pancreatic Neuroendocrine Tumors
27. Single-Cell ATAC and Single-Nucleus RNA Sequencing Uncovers Cellular Heterogeneity Within Pancreatic Neuroendocrine Tumors
28. Results of 68Gallium-DOTATATE PET/CT Scanning in Patients with Multiple Endocrine Neoplasia Type 1
29. 18F-FDG PET/CT Volumetric Parameters are Associated with Tumor Grade and Metastasis in Pancreatic Neuroendocrine Tumors in von Hippel–Lindau Disease
30. Multimodal Image Driven Patient Specific Tumor Growth Modeling
31. 225Ac-MACROPATATE: A Novel α-Particle Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors
32. Patient specific tumor growth prediction using multimodal images
33. Long-term Follow-up of MEN1 Patients Who Do Not Have Initial Surgery for Small ≤2 cm Nonfunctioning Pancreatic Neuroendocrine Tumors, an AFCE and GTE Study: Association Francophone de Chirurgie Endocrinienne & Groupe d’Etude des Tumeurs Endocrines
34. Association of VHL Genotype With Pancreatic Neuroendocrine Tumor Phenotype in Patients With von Hippel–Lindau Disease
35. Intra-Operative Indocyanine Green Angiography of the Parathyroid Gland
36. Germline- and Somatic-Inactivating FLCNVariants in Parathyroid Cancer and Atypical Parathyroid Tumors
37. Feasibility of Radio-Guided Surgery with 68Gallium-DOTATATE in Patients with Gastro-Entero-Pancreatic Neuroendocrine Tumors
38. Fibrous Dysplasia Mimicking Malignancy on 68Ga-DOTATATE PET/CT
39. 18F-FDG and 68Ga-DOTATATE PET/CT in von Hippel-Lindau Disease–Associated Retinal Hemangioblastoma
40. Breast Fibroadenoma With Increased Activity on 68Ga DOTATATE PET/CT
41. A phase II trial of valproic acid in patients with advanced, radioiodine‐resistant thyroid cancers of follicular cell origin
42. Localization of Insulinoma Using 68Ga-DOTATATE PET/CT Scan
43. 225Ac-MACROPATATE: A Novel α-Particle Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors.
44. Preoperative Imaging Features are Associated with Surgical Complications Following Carotid Body Tumor Resection
45. Resection of primary tumor site is associated with prolonged survival in metastatic nonfunctioning pancreatic neuroendocrine tumors
46. Multiple Endocrine Neoplasia Type 1 (MEN1) and the Pancreas - Diagnosis and Treatment of Functioning and Non-Functioning Pancreatic and Duodenal Neuroendocrine Neoplasia within the MEN1 Syndrome - An International Consensus Statement
47. Multiple Endocrine Neoplasia Type 1 and the Pancreas: Diagnosis and Treatment of Functioning and Non-Functioning Pancreatic and Duodenal Neuroendocrine Neoplasia within the MEN1 Syndrome - An International Consensus Statement
48. Prospective screening in familial nonmedullary thyroid cancer
49. Multimodal Image Driven Patient Specific Tumor Growth Modeling
50. Pancreatic insufficiency following pancreatectomy: Does underlying tumor syndrome confer a greater risk?
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.